Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A multicenter, randomized, open-lable, single-dose, two-cycle, double-cross bioequivalence study comparing the pharmacokinetic profile of LY01612 (Doxorubicin hydrochloride liposome injection) and CAELYX® in Chinese subjects with advanced breast cancer
Epistemonikos ID: 845d7fcc12fd0336c2d2aadec952168d749084e0
First added on: May 15, 2024